Physical activity as a resistance or resilience mechanism in Down syndrome Alzheimer's disease.
Victoria L Fleming, Jamie Peven, Brian C Helsel, Lauren T Ptomey, Julianne Clina, Ashlyn Barry, Beau M Ances, Benjamin L Handen, Bradley T Christian, Charles Laymon and 6 more
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jamie PevenBehavioral Health Service Line VA Healthcare System Pittsburgh Pennsylvania USA.
Brian C HelselDepartment of Neurology University of Kansas Medical Center Kansas City Kansas USA.
Lauren T PtomeyDepartment of Internal Medicine University of Kansas Medical Center Kansas City Kansas USA.
Julianne ClinaDepartment of Internal Medicine University of Kansas Medical Center Kansas City Kansas USA.
Ashlyn BarryWaisman Center University of Wisconsin-Madison Madison Wisconsin USA.
Beau M AncesDepartment of Neurology Washington University St. Louis Missouri USA.
Benjamin L HandenDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Bradley T ChristianWaisman Center University of Wisconsin-Madison Madison Wisconsin USA.
Charles LaymonDepartment of Radiology University of Pittsburgh Pittsburgh Pennsylvania USA.
Matthew ZammitWaisman Center University of Wisconsin-Madison Madison Wisconsin USA.
Elizabeth HeadDepartment of Pathology & Laboratory Medicine Irvine School of Medicine University of California, Irvine Orange California USA.
Mark MapstoneDepartment of Neurology Irvine School of Medicine University of California, Irvine Orange California USA.
Ozioma OkonkwoDepartment of Medicine University of Wisconsin-Madison Madison Wisconsin USA.
Sigan L HartleyWaisman Center University of Wisconsin-Madison Madison Wisconsin USA.
Alzheimer Biomarkers Consortium – Down Syndrome
Funding
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TUDORASCU, DANA L · 2020 to 2025
$103.7M
Biomarkers of Alzheimer's Disease in Adults with Down SyndromeU01AG051412 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LOTT, IRA T., SCHUPF, NICOLE · 2015 to 2019
$26.3M
University of Kansas Alzheimer's Disease Research Center (KU ADRC)P30AG072973 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI RUSSELL H. SWERDLOW · 2021 to 2026
$25.3M
NiAD Supplement WashU Start UpU01AG051406 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CONSTANTINO, JOHN N., HANDEN, BENJAMIN L · 2015 to 2019
$21.3M
Waisman Center Intellectual and Developmental Disabilities Research CenterP50HD105353 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Brittany Gail Travers · 2021 to 2026
$8.5M
Lifestyle Risk and Resiliency Factors and Alzheimer’s Disease in Down syndromeR01AG070028 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sigan L Hartley, Christy Hom · 2020 to 2026
$4.6M
Multidisciplinary Research Training Program in Alzheimer's Disease and Related DisordersT32AG078114 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Sandra A Billinger, Eric Dennis Vidoni · 2022 to 2026
$1.2M
Assessment of Physical Activity for Alzheimer's Disease Research in Down SyndromeK01AG083130 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Brian Helsel · 2023 to 2026
$501k
Body composition, physical activity, and cognitive function in Down syndromeF32AG094116 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Julianne Clina · 2025 to 2026
$157k
Weight, inflammation, and Alzheimer's disease in Down syndromeF31AG085730 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI FLEMING, VICTORIA · 2024 to 2025
introductionAdults with Down syndrome (DS) are at risk for Alzheimer's disease (AD). Lifestyle factors such as engagement in moderate-to-vigorous physical activity (MVPA) reduce risk or delay the onset of AD. This study aimed to determine whether MVPA confers a
methodsAnalyses included 69 adults with DS (aged 26-58) who participated in a longitudinal study across 3.29 years. An actigraphy accelerometer assessed MVPA across 7 days. Directly administered and informant-reported measures assessed cognitive functioning, specifically memory and dementia symptoms. Neuroimaging biomarkers quantified amyloid beta (Aβ) burden, as assessed via positron emission tomography imaging.
resultsIn regression models, baseline MVPA was not associated with baseline level or change in global Aβ burden across 32 months. However, baseline MVPA ( DISCUSSION: MVPA may help maintain cognitive functioning early in the progression of AD pathology in adults with DS. Highlights: Adults with Down syndrome are genetically at risk for Alzheimer's disease (AD).Timing of AD clinical onset spans 30+ years.Physical activity has been linked to less cognitive decline and dementia symptoms.Physical activity may protect against dementia through resilience mechanisms.Physical activity could be a low-cost intervention to help prevent cognitive decline.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Physical activity as a resistance or resilience mechanism in Down syndrome Alzheimer's disease. · full record | OpenQuestion